Talk to Your Doctor or Nurse About Your Experience with Sub-Q Infusion of Vivaglobin®

Knowing what to say to your doctor or nurse will help improve your future infusion experiences

For many people with PI, infusing Vivaglobin^® is a positive experience. And while infusion problems and side effects may occur, your Vivaglobin^® experience will likely continue to improve with each infusion.

Should you experience additional problems with your infusion routine beyond those listed on either the Side Effects page or the Common Infusion Problems page, contact your doctor or nurse to discuss your experience and ensure that your continuing experience with Vivaglobin^® is a good one.

The better you can describe your experience with your healthcare professionals, the greater chance they will be able to help you adjust your infusion routine successfully. These following tips may help you:

Offer specifics

Describe the problem in detail
Tell the doctor if you’ve experienced this problem before
Identify whether or not the problem you’re experiencing is listed on the infusion—site reaction page
Refer to the Potential Side Effects page to talk about your experience

Provide clarity

Tell your healthcare professional if you are experiencing a strong reaction or pain, or if you think you need immediate attention
Identify the exact location on your body where you’re experiencing a particular side effect
Identify which part of the infusion is the problem—the injection site, the needle, the injection tubing, the pump, or the Vivaglobin^® vial
Refer to the Potential Side Effects page to talk about your experience

Next: Useful Links

Important Safety Information

Immune Globulin Subcutaneous (Human), Vivaglobin^®, is a prescription treatment for patients with primary immunodeficiency (PI).

Immune globulin products, such as Vivaglobin^®, should not be taken if you have a history of anaphylactic or severe systemic response to immune globulin (Ig) preparations. If you suspect you are having a severe reaction to Vivaglobin^®, discontinue treatment immediately and inform your doctor.

Vivaglobin^® is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses and the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

In clinical trials, the most frequent adverse event was mild or moderate swelling, redness, and itching at the injection site. Other adverse events included headache, gastrointestinal disorder, fever, nausea, sore throat, and rash. No serious reactions were observed, and reactions tended to decrease substantially with repeated use.

If you are receiving Ig therapy for the first time, are new to Vivaglobin^®, or have not received Ig therapy within the past eight weeks, your healthcare provider should monitor your initial treatment with Vivaglobin^®, as you could experience reactions including fever, chills, nausea, and vomiting. Rarely, these reactions may lead to shock.

Ig administration may impair the effectiveness of virus vaccines, such as measles, mumps and rubella. Consult your doctor if you plan to receive any vaccine.

In clinical studies, Vivaglobin^® has been shown to be safe and well tolerated in pediatric patients, without pediatric-specific dose requirements. Safety and effectiveness were not studied in subjects under 2 years of age.

Please see full Prescribing Information and Patient Product Information.